Across TCGA pan-cancer cohorts, FABP9 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated FABP9 data layer compared with 2 for mutation status and 1 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher FABP9 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FABP9 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUSC show a favorable association.
COAD, DLBC, and SCLC are the cancer types where FABP9 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.